Eleva and 3PBIOVIAN Partner to Boost Biologics Production

Eleva has entered a strategic partnership with 3PBIOVIAN to secure clinical-grade manufacturing capacity for its biologics pipeline, including Factor H (CPV-104), a novel complement modulator targeting C3 Glomerulopathy (C3G) and dry age-related macular degeneration (dry AMD). The agreement also grants 3PBIOVIAN a non-exclusive license to Eleva’s moss-based expression system, a technology designed for efficient biologics production. With this collaboration, Eleva effectively triples its GMP manufacturing capacity, ensuring a robust supply chain for its mid- to late-stage clinical programs.

Dr. Andreas Schaaf, CSO & Managing Director of Eleva, emphasized the importance of this partnership in advancing clinical programs while expanding industry adoption of its moss-based platform. 3PBIOVIAN’s Group CEO, Dámaso Molero Sánchez, highlighted the opportunity to support Eleva’s pipeline while integrating a novel expression system into their biologics manufacturing portfolio. Eleva’s Factor H (CPV-104) is set to enter Phase 1 trials in 2025, with clinical material already secured. This collaboration strengthens Eleva’s commercialization strategy while broadening global market access for its innovative biopharmaceutical production technology.